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SUCCESSFUL SURVIVAL OF 
PRIMATES RECEIVING 
TRANSPLANTATION WITH 
"DEAD," NONBEATING 
DONOR HEARTS 
A paucity of donor organs is the principal limitation in human heart transplanta- 
tion. Prompted by our short-term studies of reanimating "dead" donor hearts in 
sheep, we applied the same reperfusion modifications in juvenile baboons to 
determine human applications in an anoxic arrest model (as occurs when non-brain- 
dead patients are extubated and allowed to die). Ten juvenile baboons (mean weight 
3.6 kg) were studied. Five baboons were used as donors. After being anesthetized, 
donors were pretreated with methylprednisolone (Solu-Medrol), 50% dextrose, 
nifedipine, and prostaglandin E 1 and then paralyzed and extubated. Donors became 
pulseless at 7 - 1 minutes and had electric arrest 9 to 18 minutes after paralysis. 
The five donors were left undisturbed and warm for 15, 22, 30, 30, and 31 minutes, 
respectively, after asystole. They were then given 250 ml of 4 ° C Roe's crystalloid 
cardioplegic solution via the aortic root and the hearts were explanted into iced 
Euro-Collins solution. Five baboons served as recipients. After donor harvest, 
recipients were placed on cardiopulmonary bypass, given prostaglandin El, and 
cooled to 18 ° C; circulatory arrest was instituted and the recipient's heart excised. 
The donor heart was transplanted in an orthotopic position. Before reinstitution of 
bypass, 250 ml of terminal leukocyte-depleted blood cardioplegic solution was given, 
then bypass was restarted and the hearts were reperfused for 60 minutes. All 
animals were weaned from bypass without the use of inotropic agents. All animals 
were extubated within 2 to 4 hours after bypass and received standard immunosup- 
pression. Peak creatine kinase MB/total creatine kinase ratio was 0.2% - 0.2%. 
Postoperative ejection fractions by echocardiography were 75% to 80% (mean 76%). 
Animals survived 1, 9, 13, 16, and 34 days, with three deaths caused by acute 
rejection and one each by stroke and diarrhea/dehydration. Pathologic findings 
showed no areas of fibrosis or ischemic damage. We conclude that successful 
reanimation and engraftment can be achieved with e use of the asystolic primate 
heart; this work suggests that human application is realistic and could greatly 
expand the donor pool. (J TnORAC CARDIOVASC SURG 1995;109:1097-102) 
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T he lack of available donors continues to thwart the further application of cardiac transplanta- 
tion. Efforts to educate the public have failed to 
produce any increase in the number of transplants 
performed. Although mechanical replacement of 
failing human hearts shows promise, the use of 
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human heart donors clearly is preferable to any 
other alternative. Prompted by our success in using 
pediatric donor hearts that had periods of arrest and 
cardiopulmonary esuscitation for up to 2 hours, we 
began a laboratory investigation into the feasibility 
of "reanimating" dead pulseless donor hearts in 
lambs. 1 Lamb hearts were successfully used for 
orthotopic heart transplantation after 1/2 hour of 
cardiac electric standstill caused by either anoxia or 
exsanguination. 2'3 Because species tolerance to 
ischemia varies widely, before application of cardiac: 
reanimation in human beings could be recom- 
mended, duplication of these results in a long-term 
subhuman primate model appeared mandatory. 
In this study we investigated the application of 
simple reperfusion modifications in a baboon heart: 
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transplant model that used "dead" hearts harvested 
from baboon donors who had had an anoxic death, 
similar to the death that occurs when patients are 
extubated and allowed to die a compassionate d ath 
when not fully brain dead. 
Material and methods 
Ten juvenile Papio baboons of 2.9 to 4.1 kg (mean 3.6 
kg) were selected as random pairs; in cases in which a size 
discrepancy existed, the larger of the two animals was 
chosen as the donor. Thus five baboons were donors and 
five were recipients. The donor baboons were anesthe- 
tized with ketamine hydrochloride, intubated, connected 
to a volume ventilator (Servo C, Siemens Corp., Ltmd, 
Sweden), and maintained with intravenous pentobarbital 
sodium. Eighteen-gauge intravascular catheters were placed 
in the femoral vessels and the arterial pressure transduced. 
No predonation functional studies were done. The electro- 
cardiogram was continuously monitored. All animals were 
given 125 mg of intravenous methylprednisolone and 10 ml 
of intravenous 50% dextrose and started receiving intrave- 
nous prostaglandin Ea at 0.1 p~g/kg per minute. A 5 mg 
capsule of nifedipine was opened and its contents adminis- 
tered sublingually. Finally, 4 mg/kg of sodium heparin was 
administered. After 5 minutes of pretreatment, the donors 
were given 2 mg of pancuronium bromide (Pavulon) and the 
ventilator was disconnected. 
Pulselessness occurred at 7 + 1 minutes after paralysis; 
baboons had electric arrest 9 to 18 minutes after paralysis. 
Animals were left undisturbed for 15, 22, 30, 30, and 31 
minutes, respectively, and then a median sternotomy was 
done. An 18-gauge catheter was inserted into the ascend- 
ing aorta, a blood sample was collected for determination 
of arterial blood gas values at the time of harvest, and the 
aorta was crossclamped. Two hundred fifty milliliters of 
Roe's crystalloid cardioplegic solution was instilled at 4 ° C 
into the aorta, with simultaneous division of both venae 
cavae. The heart was excised and placed for a mean of 1 
hour in 4 ° C Euro-Collins solution to which 5 ml of 50% 
dextrose had been added. 
After donor harvest, recipient baboons were similarly 
anesthetized, the lungs ventilated, and maintenance with 
halothane inhalation instituted. A median sternotomy was 
done, and the pericardium was incised and fashioned into 
a cradle. The animals were given 4 mg/kg of sodium 
heparin. The ascending aorta was cannulated through a 
purse-string suture for arterial inflow and the right atrial 
appendage cannulated for venous egress to the pump 
oxygenator. Animals were placed on cardiopulmonary 
bypass support with use of an asanguineous priming 
solution and cooled to a rectal temperature of 20 ° C. 
Once cardiopulmonary b pass was begun, administra- 
tion of prostaglandin Ea was started at 0.1 p~g/kg per 
minute and continued until 30 minutes before gradual 
removal from bypass. At the same time, a 5 mg nifedipine 
capsule was opened and its contents administered sublin- 
gually. After cooling was completed, the ascending aorta 
was crossclamped and profound hypothermic arrest was 
instituted. Cardiac transplantation was done in our usual 
fashion with the "dead" donor heart after the recipient's 
heart was excised. 4 The venous cannula was reinserted 
into the donor's fight atrium. Through a separate aortic 
purse-string suture, an 18-gauge cannula was inserted into 
the ascending aorta. The left atrial appendage was vented, 
and the baboon was given 250 ml of leukocyte-depleted 
terminal blood cardioplegic solution into the aortic root. 
The baboon was placed back on bypass and rewarmed. 
The hematocrit value of the animal was concentrated up
to 0.30 with an in-line ultrafilter circuit and calcium 
repleted uring a further 50-minute rewarming period. All 
five hearts returned to sinus rhythm before removal of 
bypass. No inotropic support was given. 
After the termination of bypass and reversal of heparin 
with protamine sulfate, all baboons' chests were closed 
without drainage catheters. All animals were extubated 
within 4 hours of the operation and begun on oral 
feedings the first postoperative day. Blood was drawn 
before and after bypass and daily for 3 days for determi- 
nation of creatine kinase (CK) and CK-MB fractions. 
Transthoracic e hocardiograms were obtained every other 
day. Cyclosporine was given orally at 30 to 50 mg/kg daily, 
azathioprine was administered orally at 3 mg/kg daily, and 
125 mg methyl prednisolone (Solu-Medrol) was adminis- 
tered intravenously on the first postoperative day. Rejec- 
tion episodes were treated with intravenous teroid bo- 
luses. When death occurred, autopsies were done to 
determine the cause of death and hearts were examined 
microscopically for evidence of ischemic damage and 
rejection. 
Results 
Donor hearts were harvested 15, 22, 30, 30, and 31 
minutes after electric cardiac arrest. All hearts 
regained sinus rhythm and all hearts were weaned 
from cardiopulmonary b pass without inotropic sup- 
port. All animals were extubated from 2 to 4 hours 
after operation. Transthoracic echocardiograms 
demonstrated ejection fractions from 75% to 80% 
(mean 76%). The mean peak CK-MB/total CK ratio 
was 0.2 _ 0.2, with no heart eluting a large amount 
of myocardial CK, thus confirming the lack of 
significant ischemic damage. 
Animals survived 1, 9, 13, 16, and 34 days, with the 
death on day 1 caused by a stroke and the death on 
day 9 by dehydration. All other deaths were due to 
rejection. Autopsy on explanted hearts demon- 
strated minimal to no ischemic damage (Figs. 1 and 
2), whereas rejecting hearts showed typical changes 
of grade 3 to 4 rejection. 
All animals received humane care in compliance 
with the "Principles of Laboratory Animal Care" 
formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of 
Laboratory Animal Resources and published by the 
National Institutes of Health (NIH Publication No. 
86-23, revised 1985). 
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Fig. 1. Photomicrograph of transplanted " ead" heart 9 days after operation showing no ischemic hanges 
and normal myofibrillar architecture. 
Fig. 2. Photomicrograph of transplanted "dead" heart showing minimal cellular loss perivascularly 
compatible with rejection or ischemic injury. 
Discussion 
It has been assumed that anoxically arrested 
hearts would be poor donors for cardiac transplan- 
tation, in that the energy stores of the heart would 
be severely depleted and that on reperfusion, con- 
traction band necrosis would invariably occur. 5Coo- 
per 6 and Lundsgaard-Hansen a d associates, 7 work- 
ing independently, had poor results with such an 
animal model. However, since 1985 our clinical 
success with the use of infant and pediatric donor 
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hearts that had been successfully resuscitated after 
arrest imes of up to 1 hour prompted us to study 
how reperfusion modifications might enable "dead" 
hearts to be reanimated and used immediately as 
donor organs. 1's, 9 
Short-term experiments in lambs with both anoxic 
and exsanguination models confirmed that reperfu- 
sion modifications, with or without donor pretreat- 
ment, could reliably and consistently produce "nor- 
mal" donor hearts even after 30 minutes of warm 
ischemia. Pretreatment of the recipient with sublin- 
gual nifedipine; prostaglandin E 1 infusion; and 
reperfusion with a low hematocrit value (3% to 5 %), 
low ionized calcium (0.3 to 0.5 mg/dl), low pressure 
(mean arterial pressure 20 mm Hg), and low flow 
(25 ml/m 2) blood reperfusate was successful in pro- 
ducing short-term successful orthotopic transplanta- 
tion and reanimation of these "dead" hearts. 2'3 
However, because of species differences and the 
lack of long-term results, direct applicability to 
human beings could not be assured. 
In this experiment, as in the anoxic lamb model, 
donors were pretreated with steroids, prostaglandin, 
nifedipine, and dextrose, and recipients received the 
same reperfusion modifications as noted for the 
lamb model. Additionally, a leukocyte-depleting fil- 
ter was added to the terminal blood cardioplegic 
solution, in large part because of the success of this 
intervention i hearts preserved for greater than 24 
hours. 1° 
The lack of a significant reperfusion injury or 
permanent ischemic damage is attested to by the 
lack of CK-MB band elaboration, the lack of acute 
or chronic fibrotic/ischemic changes in the myocar- 
dium on postmortem examination, and the normal 
ejection fractions. These findings echo those seen in 
our patient population, in which neither short- nor 
long-term changes of ischemic damage have been 
seen in transplanted but previously arrested 
hearts.i, 8,9 Although long-term survival in our se- 
ries was not achieved, with three animals dying as a 
result of rejection 2 to 5 weeks after operation, we 
did not use high eyclosporine l vels (range 180 to 
266 mg/dl by monoclonal antibody) or FK 506, a 
drug that we have previously shown produces superb 
long-term survival in baboons, even those receiving 
transplant with xenografts. 1~Because we have not 
seen accelerated rejection in hearts with long isch- 
emic times, or in previously resuscitated hearts, 9'12 
we doubt hat the deaths caused by rejection in this 
laboratory series can be attributed to ischemic in- 
jury. 
In conclusion, Baboon hearts recovered 15 to 31 
minutes after cardiac standstill caused by anoxia can 
be transplanted, reperfused, and reanimated with- 
out difficulty with the use of clinically applicable 
methods. These data suggest hat use of these 
techniques in human beings is feasible. If applied, 
the use of donors with nonbeating hearts could be 
extended to cardiac transplantation, thus greatly 
expanding the donor pool. 
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Discussion 
Dr. Adnan Cobanoglu (Portland, Ore.). During the past 
5 years Dr. Gundry and his colleagues at Loma Linda have 
given excellent reports on marginal resuscitated pediatric 
donors and reanimated onors in juvenile lamb models, 
and this study is a natural extension of their prior work. 
There has been a steady increase in the number of 
patients waiting for transplantation. As of May 1994 there 
were 2900 patients on the waiting list for heart transplan- 
tation in the United States. Only 1900 to 2000 transplants 
are done a year and the attrition rate while waiting may be 
as high as 40% on some of the lists. In an attempt to meet 
an ever-increasing demand for organs, most programs 
have extended the criteria for graft acceptability. The 
upper limit of the acceptable donor age was the first area 
that was liberalized. The second area has been acceptance 
of the so-called marginal donors. These are donors who 
do not fit the hemodynamic criteria for acceptance, those 
who have had prolonged cardiopulmonary esuscitation, 
or those receiving large doses of inotropic drugs or who 
have compromised left ventricular function. 
Our experience in Portland with 250 transplants and 
our recent review for the Society of Thoracic Surgeons 
program have shown that with careful preoperative and 
intraoperative management of the donor heart a signifi- 
cant number of these marginal hearts, even those with up 
to 30 to 40 minutes of cardiac massage and resuscitation 
and those initially receiving 20 to 30 txg of dopamine or 
the equivalent, can be salvaged and successfully used for 
transplantation. 
Dr. Gundry's report takes this issue one step further. 
He has demonstrated that at least in the laboratory setting 
and in a subhuman primate, the juvenile baboon, success- 
ful heart transplantation is possible from not only brain- 
dead but also heart-dead onors. These are donor hearts 
with warm asystolic ischemia. This study is analogous to 
the discontinuation f ventilatory support for compassion- 
ate reasons in persons in vegetative states or in those who 
are hopelessly ill but are potential organ donors in whom 
a cardiac arrest and asystole will occur after the ventilator 
support is stopped. 
I congratulate the authors for exploring this frontier, 
and I have a few questions. Studies have shown different 
responses to ischemia or anoxia, or both, in mature versus 
immature myocardium. Is your study clinically applicable 
to all donors or just to the younger ones, that is, neonates 
and young infants? 
Dr. Gundry. These baboons are juveniles, that is, they 
are around 9 months to a year old and in a baboon lifetime 
this is equivalent o a teenager. Our studies at Loma 
Linda involving clinical donors have shown no difference 
in the tolerance of adult hearts and infant hearts to 
ischemia, so I would like to think that we could extrapo- 
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late these findings in a teenage model to a fully adult 
model. 
Dr. Cobanoglu. Did you evaluate the amount of myo- 
cardial injury by means other than the CK-MB fraction 
such as myosin light chain efflux or other biochemical 
parameters? 
Dr. Gundry. No. We looked at myosin light chain etttux 
in a clinical study that Dr. Kawauchi in our laboratory did 
and found that the light chain etttux correlated very well to 
the CK-MB band and also to late myocardial fibrosis. In 
following the CK-MB band, plus the echocardiography 
and the lack of inotropic support, we are fairly comfort- 
able that no major ischemic damage was done. 
Dr. Cobanoglu. The duration of total ischemic time will 
be another important factor in the clinical setting. Will 
this method be applicable in the clinical setting where 3 or 
more hours of ischemia is common? 
Dr. Gundry. That is an area of new investigation. We 
wanted to mimic a clinical setting in which a patient could 
be extubated in the intensive care unit even with the 
family present and allowed to die. Then the patient would 
simply be heparinized in that state and the surgical team 
either in the intensive care unit or available in a room next 
door would explant he heart. I think it is practical to 
obtain these hearts in 1/2 hour. It remains to be seen 
whether we can take someone from outside the hospita][ 
who has been dead for several hours and do the same 
manipulations. 
Dr. Cobanoglu. When do you plan to take the next step 
from subhuman primates to human patients? Do you plan 
to use these reanimated hearts in high-risk recipients o1: 
on all comers, including status II patients? 
Dr. Gundry. We are studying that question with our 
institutional review board right now. There is an ethical 
question and also a legal question as to the definition of 
death. If the definition of death is the irreversible cessa- 
tion of heartbeat (which is the common definition of death 
in most states), does that apply to irreversible cessation of 
heartbeat in that particular person or does it apply to 
when that heart is removed, implanted in someone lse, 
and then started again? Is that the same thing? Our legal 
team has advised us that the potential exists that we could 
be charged with murder by doing this particular procedure 
without legislative change in the law of defining death, so 
we are in limbo at this point. Obviously donors with 
nonbeating hearts are used in the kidney and liver fields, 
but again surgeons are not required to use that heart, 
which still remains dead in that patient. 
Dr. Cobanoglu. Other than the murder charge, I think 
there is somewhat of an ethical decision here, because the 
donor heart is really dead when you accept it. How will 
you inform the patient? Will you tell him or her that you 
have a "good dead heart" available? 
Dr. Gundry. I think many of our patients who are in 
extremis would be more than happy to take a dead heart 
from somebody else, particularly given the evidence that 
these hearts are resuscitatable. We certainly use older 
hearts on older recipients now, something that was un- 
thinkable several years ago, and I can assure you that my 
older recipients are perfectly happy to have an older heart 
as long as they are alive. I think this is just one more step 
in a direction that we have to go as soon as the legal 
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ramifications are worked out, and I am sure they can be. 
The point of this paper is this is the next step and it can be 
done. 
Dr. Dimitri Novitzky (Tampa, Fla.). This is a nice 
animal model, but I think clinical implementation is very 
unlikely. In Cape Town we induced experimental brain 
death in baboons and documented a massive autonomic 
response in which there is a significant increment of 
circulating and endogenous catecholamine r lease that 
induces diffuse myocardial injury. There is marked suben- 
docardial injury, as well as scattered myocyte necrosis. 
These observations occur as early as 30 minutes after 
induction of brain death. Pretreatment with calcium 
blockers such as verapamil abolished the catecholamine- 
induced injury without observation of histologic myocyte 
necrosis. 
I would like to ask you how the initial neurologic 
(sympathetic) impact observed in our animal model and 
human donor hearts will be prevented? In this particular 
experimental model, after anesthesia and calcium blocker 
pretreatment, anoxic brain death is induced, which there- 
fore avoids catecholamine-induced injury. 
In a clinical setting, I find it hard to believe this can be 
applied. The brain-dead organ donors, during the agonal 
period, already have been exposed to the catecholamine- 
induced injury. The slide you showed us had a normal 
histologic subendocardium similar to the experiments 
done by us. 
Dr. Gundry. I agree with you that from some experi- 
mental studies this is true. However, in all of our labora- 
tory studies with this identical model we have yet to 
produce that subendocardial njury. I think it is secondary 
to the modifications of how reperfusion is done. Of 
course, the big fear with the use of marginal donors was 
that these donors had huge catecholamine storms and had 
marginal myocardial conditions with a very low ejection 
fraction by echocardiography and huge amounts of ino- 
tropic support. The fear was that these were severely 
damaged hearts that would not work in human subjects. In 
fact, as Dr. Cobanoglu has pointed out and in our study, 
this simply does not happen when these hearts are trans- 
planted. When they are taken out of the deleterious 
milieu of the brain-dead onor and put in a normal human 
being, these hearts respond normally, and their inotropic 
support is minimal. Even patients whose donor hearts 
have received norepinephrine, epinephrine, and huge 
amounts of dopamine are weaned from cardiopulmonary 
bypass with minimal inotropic support in the normal 
milieu of a healthy brain, if you will. 
Additionally, Dr. Javier Alonzo de Begona, at our 
institution, has looked at the amount of fibrosis in hearts 
recovered from children who have had as long as i hour of 
downtime before cardiopulmonary esuscitation, a study 
that now extends to 8 years after transplantation, and has 
found no difference in the amount of myocardial fibrosis 
or in the ejection fraction of these hearts in human beings 
compared with these findings in hearts from donors who 
have not had cardiopulmonary resuscitation and have not 
had downtime. I suspect that in fact these laboratory data 
are directly transferable to the human subject. 
